A manufacturer of primarily generic products had made an advancement in the formulation of a standard hospital antibiotic.  They wanted to bring two novel formulations to market and asked us to provide insights on the likely use and appropriate pricing of each formulation.

A large pharmaceutical company was launching a novel compound into an orphan oncology space and wanted to segment payers in order to anticipate the response and ensure the best possible access.

A large global pharmaceutical company had a hematology product that had long since been surprised by newer drugs, but still brought in significant revenues.  They asked us to produce a pricing tracker to improve their ability to respond and predict multiple markets and refine their value strategy.

A large pharmaceutical company had a well-known and profitable respiratory franchise.  As they prepared to launch a novel combination product, they asked for us to conduct a comprehensive pricing study, taking into account multiple stakeholders and the impact of the new product on the rest of their portfolio.

A clinical stage biotech company was building up commercial operations for a novel anti-epileptic.  They asked us to provide a snapshot of the reimbursement landscape they could expect, and to help them  price their product for optimal revenues and access.